Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as compared with imatinib, for the primary-line cure of CML-CP. 5 hundred and nineteen people with newly diagnosed CML-CP had been randomly assigned to get dasatinib in a dose of one hundred mg at the time day by day https://jamesd186vae9.blogrenanda.com/profile